P-005 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01908-6

Sébastien Anguille, Xavier Leleu, Moshe Gatt, Lionel Karlin, Andrew Spencer, Shinsuke Iida, Tadao Ishida, Yi Lin, Chang-Ki Min, Seok Jin Kim, Ana Slaughter, Carolina Lonardi, Nina Benachour, Martin Vogel, Vicki Plaks, Katherine Li, Diana Chen, Quanlin Li, Tamar Lengil, Mythili Koneru, Hermann Einsele

引用次数: 0

查看原文本刊更多论文

P-005 桥接疗法的有效性与接受CAR-T疗法后的疗效改善相对应：复发、来那度胺难治性多发性骨髓瘤患者的3期CARTITUDE-4研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.